標(biāo)題: Titlebook: Immunotherapy; Aung Naing,Joud Hajjar Book 2021Latest edition The Editor(s) (if applicable) and The Author(s), under exclusive license to [打印本頁] 作者: 選民 時間: 2025-3-21 18:44
書目名稱Immunotherapy影響因子(影響力)
書目名稱Immunotherapy影響因子(影響力)學(xué)科排名
書目名稱Immunotherapy網(wǎng)絡(luò)公開度
書目名稱Immunotherapy網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Immunotherapy被引頻次
書目名稱Immunotherapy被引頻次學(xué)科排名
書目名稱Immunotherapy年度引用
書目名稱Immunotherapy年度引用學(xué)科排名
書目名稱Immunotherapy讀者反饋
書目名稱Immunotherapy讀者反饋學(xué)科排名
作者: 試驗 時間: 2025-3-21 20:48
Resistance to Immunotherapy: Mechanisms and Means for Overcoming,r over the course of treatment, and many patients with PD-L1-expressing tumors do not respond to PD-(L)1 blockade. In addition, while some malignancies exhibit inherent resistance to treatment, others develop adaptations that allow them to evade antitumor?immunity after a period of response. It is c作者: 輕打 時間: 2025-3-22 03:46 作者: 青石板 時間: 2025-3-22 06:48
Immunotherapy in Lung Cancer: Are the Promises of Long-Term Benefit Finally Met?,iple clinical settings. Inhibitors of PD-1/PD-L1 have been approved for the treatment of different types of lung cancer by the FDA either alone or in combination with chemotherapy or other immune checkpoint inhibitors, such as anti-CTLA-4 agents. The introduction of these agents in clinical practice作者: prostate-gland 時間: 2025-3-22 08:44
Landscape of Immunotherapy in Genitourinary Malignancies,itourinary cancers. Immune checkpoint inhibitors have notably improved the treatment outcomes of patients with metastatic renal cell carcinoma and metastatic urothelial carcinoma. In prostate cancer, the role of immunotherapy with checkpoint inhibitors is not yet established except for microsatellit作者: 知識 時間: 2025-3-22 15:35
Immuno-Oncology for Gynecologic Malignancies,s of immunotherapy in other difficult-to-treat malignancies such as metastatic melanoma and advanced lung cancer have led to intense interest in clinical testing of these treatments in patients with gynecologic cancers. Currently, in the realm of gynecologic oncology, the FDA-approved use of immune 作者: expansive 時間: 2025-3-22 20:22
Immunotherapy for Neuro-oncology,eral circumstances unique to the central nervous system (CNS) such as limited space for an inflammatory response, difficulties with repeated sampling, corticosteroid use for management of cerebral edema, and immunosuppressive mechanisms within the tumor and brain parenchyma have posed challenges in 作者: chemical-peel 時間: 2025-3-22 22:02
Immunotherapy in Gastrointestinal Malignancies,ment and subsequent prognosis. The interplay between tumor cells and the local immune microenvironment also varies within each GI malignancy and can portend prognosis and response to therapy. Treatment with immune checkpoint inhibitors has changed the treatment landscape of various solid tumors incl作者: ENACT 時間: 2025-3-23 01:45 作者: 審問,審訊 時間: 2025-3-23 07:13
CAR T Cells,xploit the power of immunotherapy however was forestalled by an era of chemotherapy that ensued. During World War II, the accidental sinking of a US naval ship led to a group of sailors developing pancytopenia due to poisoning from mustard gas (nitrogen mustard). The observation prompted wide-scale 作者: 潔凈 時間: 2025-3-23 16:13
Immunotherapy-Mediated Luminal Gastrointestinal Toxicities, and survival. As beneficial as these class of drugs have been proven to be, their use is not devoid of complications, viz., immune-related adverse events (irAEs). The gastrointestinal (GI) tract is the second most frequently affected organ system, and toxicities may vary in severity from mild disea作者: gratify 時間: 2025-3-23 20:45
Hepatobiliary and Pancreatic Adverse Events,atment selection and survival..Hepatotoxicity is a well-recognized immune-related adverse event (irAE) associated with treatment with ICI. It is considered a type of drug-induced liver injury (DILI). Depending on the specific ICI and whether the patient receives single- or dual-drug therapy, the inc作者: 吞沒 時間: 2025-3-23 23:22 作者: scotoma 時間: 2025-3-24 03:28 作者: 碌碌之人 時間: 2025-3-24 10:09 作者: Adrenaline 時間: 2025-3-24 14:12 作者: Lyme-disease 時間: 2025-3-24 18:09
Neurologic Toxicities of Immunotherapy,f growing spectrum of immune-related adverse events (irAEs) due to cross-reactivity between the tumor and normal host tissue. These adverse events can happen in any organ and range from mild to severe and even life-threatening conditions. While neurological irAEs associated with immune checkpoint in作者: 取之不竭 時間: 2025-3-24 20:21 作者: 褲子 時間: 2025-3-25 01:05
Anusha S. Thomas,Yinghong Wang This tissue is highly vascularised and responsible for nutrient supply and waste removal. In addition, it contains an immune system as a defence against invading bacteria. Nevertheless, penetration of cariogenic bacteria can lead to necrosis of the tissue and blood vessels. Although current endodon作者: aerial 時間: 2025-3-25 04:16 作者: Subdue 時間: 2025-3-25 11:25
Abdulrazzak Zarifa,Juan Lopez-Mattei,Nicolas L. Palaskas,Cezar Iliescu,Jean-Bernard Durand,Peter Y. tinued to be the case despite recent advances in the treatment of acute events, which have proven to decrease disability and improve outcomes. Over recent years, there has been significant growth in the field of acute stroke care and stroke systems of care. This includes improvements in the manageme作者: 群居男女 時間: 2025-3-25 14:22 作者: Proponent 時間: 2025-3-25 17:57 作者: murmur 時間: 2025-3-25 23:54
Immunotherapy for Melanoma,n, we provide an overview of the results of recent advances in the adjuvant setting for patients with resected stage III and stage IV melanoma, as well as in patients with melanoma brain metastases. Finally, we provide a brief overview of the current research efforts in the field of immuno-oncology for melanoma.作者: 粗魯?shù)娜?nbsp; 時間: 2025-3-26 00:16 作者: 慟哭 時間: 2025-3-26 07:50
Immune Checkpoint Inhibitor (ICI)-Related Cardiotoxicity,toxicities related to immunotherapy are reportedly rare, they can be severe and associated with life-threatening conditions such as fulminant myocarditis, hemodynamic instability, and cardiac arrest. We will review the most commonly reported cardiovascular toxicities associated with ICIs and their management.作者: noxious 時間: 2025-3-26 08:36 作者: 騷動 時間: 2025-3-26 13:16
Resistance to Immunotherapy: Mechanisms and Means for Overcoming,rucial to understand the pathophysiology of the tumor-immune system interplay and the mechanisms of immune escape in order to circumvent primary and acquired resistance. Here we provide an outline of the most well-defined mechanisms of resistance and shed light on ongoing efforts to reinvigorate immunoreactivity.作者: forecast 時間: 2025-3-26 16:49
Renal Toxicity, autoimmune disease with a focus on renal cell cancer in setting of chronic kidney disease (CKD). Transplant rejection in setting of CPI use has been further evaluated with single-center and multicenter retrospective studies, and available data will be presented in this chapter.作者: 禁止 時間: 2025-3-27 00:10 作者: Condescending 時間: 2025-3-27 01:37 作者: 有組織 時間: 2025-3-27 08:20 作者: choroid 時間: 2025-3-27 12:17
Skin Reactions to Immune Checkpoint Inhibitors,patients, 43.5% have a cutaneous AE, and, at our institution, 20% of them had a dose interruption as a result. This means potentially 9% of patients have dose interruption of ipilimumab because of their cutaneous AEs. In the following chapter, we review the categories of these drugs, common cutaneous effects, their grading, and management options.作者: AORTA 時間: 2025-3-27 17:00
Immune-Related Oral, Otologic, and Ocular Adverse Events,onal chemotherapy are well known, the toxicity profile of emerging immune therapies is not fully elucidated. They have been associated with atypical side effects labeled collectively as immune-related adverse events (irAEs).作者: POWER 時間: 2025-3-27 17:56 作者: Tailor 時間: 2025-3-28 02:00
0065-2598 me the challenges associated with immunotherapy.Presents cut.The field of immuno-oncology continues to rapidly evolve as new insights to fight and treat cancer emerge. The fourth edition of?.Immunotherapy.?provides the most current overview of immuno-oncology in different cancer types and toxicities作者: 吃掉 時間: 2025-3-28 06:06
The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerl作者: miniature 時間: 2025-3-28 09:42 作者: 欺騙手段 時間: 2025-3-28 10:45 作者: Somber 時間: 2025-3-28 15:24
Advances in Experimental Medicine and Biologyhttp://image.papertrans.cn/i/image/462297.jpg作者: employor 時間: 2025-3-28 22:04
https://doi.org/10.1007/978-3-030-79308-1biomarkers; immune checkpoint inhibitors; resistance to therapy; immune-related adverse events; patient-作者: Dealing 時間: 2025-3-28 23:37
Landscape of Immunotherapy in Genitourinary Malignancies, development to predict response to immunotherapy and risk of toxicity. This book chapter is a comprehensive review of immunotherapeutic approaches, both approved and investigational, for the treatment of renal cell carcinoma, urothelial carcinoma, and prostate cancer.作者: Maximize 時間: 2025-3-29 05:54 作者: mortuary 時間: 2025-3-29 09:32 作者: Infect 時間: 2025-3-29 12:27 作者: 官僚統(tǒng)治 時間: 2025-3-29 18:50
CAR T Cells, this field involve “taking the breaks off” and “pushing the pedal” of the immune system. These therapies, namely, immune checkpoint inhibitors and adoptive cell therapy, respectively, have been successful in a variety of malignancies, while the former mostly in solid tumors and the latter in hemato作者: CRP743 時間: 2025-3-29 20:48
Hepatobiliary and Pancreatic Adverse Events,nts may present with jaundice, fever, or malaise. Rarely, it may cause liver failure and death. The diagnosis of IMH is made after careful exclusion of other causes of acute hepatitis based on medical history, laboratory evaluation, imaging, and liver histological findings. In clinically significant作者: Virtues 時間: 2025-3-30 02:10 作者: FELON 時間: 2025-3-30 06:48 作者: 整潔 時間: 2025-3-30 08:53 作者: CRACY 時間: 2025-3-30 16:26 作者: 喃喃訴苦 時間: 2025-3-30 19:27 作者: Pigeon 時間: 2025-3-31 00:28
Nazanin K. Majd,Pushan R. Dasgupta,John F. de Groot作者: emission 時間: 2025-3-31 03:04 作者: Pericarditis 時間: 2025-3-31 05:51
Book 2021Latest editionisions..The fourth edition will have a new focus on strategies to overcomethe challenges associated with immunotherapy. Chapters will discuss topics such as biomarkers of response, resistance mechanisms, role of imaging in predicting immune-related adverse events, and management of immune-related ad作者: 注意 時間: 2025-3-31 09:17 作者: 惰性女人 時間: 2025-3-31 14:42
Mehmet Altan,Linda Zhong,Vickie R. Shannon,Ajay Sheshadri some of the new advances in care for the acute stroke patient, as well as the benefits of a stroke unit approach to care. Some of the basic components that make a successful stroke unit will be reviewed, and the development of telemedicine will be introduced when considering the future practice of 作者: 隱士 時間: 2025-3-31 17:30
Abdulrazzak Zarifa,Juan Lopez-Mattei,Nicolas L. Palaskas,Cezar Iliescu,Jean-Bernard Durand,Peter Y. some of the new advances in care for the acute stroke patient, as well as the benefits of a stroke unit approach to care. Some of the basic components that make a successful stroke unit will be reviewed, and the development of telemedicine will be introduced when considering the future practice of 作者: negligence 時間: 2025-4-1 00:18 作者: Mercurial 時間: 2025-4-1 04:38 作者: VICT 時間: 2025-4-1 08:54
Gayatri Sakya,Shivam,Naina Rani,Tanu Tripathi,Satvik Vats of computer vision whose work is related to human–computer interaction..The 11 papers presented in this volume were carefully reviewed and selected from 27 submissions. They address a wide range of theoretical and application issues in human–computer interaction. There were four thematic sessions n作者: 食品室 時間: 2025-4-1 13:45
Enzymatic Modification of Starch for Surface Sizing, modification is applicable to different types of starches although the operating conditions in terms of enzyme dose and reaction time may vary. Enzyme-modified starch is available from starch producers or can be produced on site at the paper mill using a batch or continuous process.作者: backdrop 時間: 2025-4-1 15:56 作者: 召集 時間: 2025-4-1 19:28
Discrete-Time Sliding Mode Protocols for Leader-Following Consensus of Homogeneous Discrete Multi-Ang mode protocols designed by Gao’s reaching law and Power rate reaching laws are presented. The discrete multi-agent system is configured for communication with a fixed, undirected graph topology having one leader and other agents as followers. The sufficient condition for global stability is estab作者: nurture 時間: 2025-4-1 22:57 作者: 說明 時間: 2025-4-2 04:10
Einleitung,Mitte 1941 an einem in der Folge zunehmenden linksseitig betonten Parkinson-Syndrom (Gibbels 1988). Auch in der Vorkriegs?ra war gelegentlich eine leichte habituelle Minderbewegung des linken Armes zu beobachten — m?glicherweise Folge der linksseitigen Schulterverletzung beim Putsch vom 9. November
